Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 47 · MACD below its signal
None of the 29 investors followed here reported a position in INNMF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INNMF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2025 | Bell (Jane Catherine)Independent Non-Executive Director | Other at price 0.15 per share. | 130.4K | $19.64K |
| Aug 31, 2025 | Burns (Christopher John)Chief Executive Officer | Other at price 0.15 per share. | 87K | $13.10K |
| Aug 31, 2025 | Peach (Robert James)Independent Non-Executive Director | Other at price 0.15 per share. | 652.2K | $98.22K |
| Aug 31, 2025 | Tong (Warwick Bonner)Independent Non-Executive Chairman | Other at price 0.15 per share. | 152.2K | $22.92K |
| May 14, 2025 | Peach (Robert James)Independent Non-Executive Director | — | 1.91M | — |
| Dec 19, 2024 | Bell (Jane Catherine)Independent Non-Executive Director | — | 695.7K | — |
| Dec 19, 2024 | Burns (Christopher John)Chief Executive Officer | — | 347.8K | — |
| Dec 19, 2024 | Tong (Warwick Bonner)Independent Non-Executive Chairman | — | 695.7K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 26.6 | -40.0 | 208.3 | -29.7 | -26.9 | 21.1 | -21.7 | 11.1 | -15.0 | -11.8 | −5.1% | ||
| 2025 | -31.7 | 167.9 | -34.7 | -28.6 | 8.6 | 305.3 | 11.0 | -31.0 | -15.3 | -20.0 | 15.0 | -14.1 | +92.7% |
| 2024 | 17.3 | -18.0 | 0.0 | -2.0 | -8.2 | -11.1 | 75.0 | 25.7 | 2.3 | 52.2 | -57.7 | -29.3 | −21.2% |
| 2023 | 15.4 | -41.7 | 85.7 | 0.0 | -21.5 | 17.6 | -25.0 | 13.3 | -2.0 | 8.0 | -53.7 | 108.0 | 0.0% |
| 2022 | -3.5 | 6.4 | -7.8 | -11.2 | -16.8 | -16.5 | -4.5 | 12.7 | 0.0 | -11.3 | -36.5 | 30.0 | −54.0% |
| 2021 | 20.5 | -16.6 | 13.6 | -22.6 | 1.2 | -13.5 | -10.9 | 10.7 | 3.4 | -13.3 | -13.1 | −40.5% |
No analyst coverage for this instrument.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.